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bronchoalveolar lavage fluid
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Abstract
Background: The diagnosis of active pulmonary tuberculosis (TB) remains a challenge in clinic, especially for
sputum negative pulmonary TB. Bronchoalveolar lavage fluid (BALF) has higher sensitivity than sputum for
detection of Mycobacterium tuberculosis (Mtb). However, bronchoscopy is invasive and costly, and not suitable for
all patients. In order to make TB patients get more benefit from BALF for diagnosis, we explore which indicator
might be used to optimize the choice of bronchoscopy.
Methods: A total of 1539 sputum-smear-negative pulmonary TB suspects who underwent bronchoscopy were
recruited for evaluation. The sensitivity, specificity and accuracy of Mtb detection in sputum and BALF were
compared. Odds ratios and 95% confidence intervals were used to assess variables that associated with positive
acid-fast bacilli (AFB) smear, Mtb culture and nucleic acid amplification test (NAAT) of BALF in sputum-negative and
non-sputum-producing pulmonary TB suspects.
Results: BALF has significantly higher sensitivity (63.4%) than sputum (43.5%) for Mtb detection by culture and
NAAT. 19.7% (122/620) sputum-negative and 40.0% (163/408) non-sputum-producing suspects had positive
bacteriological results in BALF. Among sputum-negative and non-sputum-producing pulmonary TB suspects, the
positivity of Mtb detection in BALF is associated with a younger age, the presence of pulmonary cavities and a
positive result of interferon-gamma release assay (IGRA). Sputum-negative patients under 35 years old with positive
IGRA and pulmonary cavity had 84.8% positivity of Mtb in BALF.
Conclusions: Our study indicated that combination of age, the presence of pulmonary cavity, and the result of
IGRA is useful to predict the positivity of Mtb detection in BALF among sputum-negative and non-sputum
producing pulmonary TB suspects. Those who are under 35 years old, positive for the presence of pulmonary cavity
and IGRA, should undergo bronchoscopy to collect BAFL for Mtb tests, as they have the highest possibility to get
bacteriologically confirmation of TB.
Keywords: Pulmonary tuberculosis, Predictive factors, Bronchoalveolar lavage fluid, Mycobacterium tuberculosis,
Detection
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Background
Tuberculosis (TB), an airborne infection caused by Myco-
bacterium tuberculosis (Mtb), remains a major global
health problem. In 2015, there were estimated 10.4 million
new TB cases, and 1.8 million TB deaths. Despite this
large toll of mortality, majority of TB patients can be
cured within 6 months with timely diagnosis and correct
treatment [1]. Considering there is no effective preventive
vaccine against TB, the early diagnosis of pulmonary TB
patients is not only critical for individual treatment, but
also a major strategy for prevention of TB transmission.
Microbiological confirmation of TB and drug susceptibil-
ity testing are key factors ensuring that new TB suspects
are accurately diagnosed and timely accessible to effective
treatment. Unfortunately, it remains as a challenge as up
to 65% of TB patients were negative for Mtb detection in
China [1]. There is a clear necessity to identity optimal
methods for pulmonary TB diagnosis of bacteriologically-
negative patients, particularly in high burden settings of
multi-drug resistant TB (MDR-TB) like China.
Newer methods with increased sensitivity compared to
traditional acid-fast bacilli (AFB) smear and culture have
been developed during the last decades [2]. For example,
molecular DNA-based diagnostics such as Xpert MTB/
RIF [3] and line probe assays (LPAs) [4], have become
widely available and permit both rapid diagnosis and pre-
liminary assessment of drug susceptibility [5]. While by
smear, culture and nucleic acid amplification test (NAATs)
have made an important contribution by accelerating TB
diagnosis and preliminary identification of MDR-TB, the
sensitivity remains too low [6]. Consequently, a substantial
proportion of pulmonary TB patients are diagnosed based
only on symptoms, chest X-ray abnormalities or (rarely)
characteristic histopathology [7]. In China, the positive
rate of bacteriologically confirmed pulmonary TB is only
35% among 1.38 million pulmonary TB cases [1]. Among
these patients, some were bacteriologically negative due to
lack of sputum or false-negative due to poor sputum sam-
ple quality. Bronchoscopy has demonstrated superiority to
expectorated sputum for pulmonary TB diagnosis. As an
example, a recent study reported that 54% of sputum-
negative pulmonary TB patients were eventually con-
firmed by finding Mtb in BALF samples by NAAT or cul-
ture [8].
Although BALF offers the potential to improve the posi-
tivity of microbiological finding for diagnosis of pulmon-
ary TB, bronchoscopy is invasive and costly. In order to
maximize the benefit of bronchoscopy while minimizing
the cost to TB control programs, it is important to identify
parameters to predict the yield of BALF for diagnosis of
sputum- negative pulmonary TB [9]. In the present study,
we compared the sensitivity and specificity of Mtb tests
between sputum and BALF for diagnosis of pulmonary
TB among 1539 sputum-smear-negative cases, and identi-
fied clinical parameters which are associated with the
benefit of bronchoscopy in sputum-negative and non-
sputum-producing pulmonary TB suspects.
Methods
Study population
This retrospective study was conducted at Shenzhen
Third People’s Hospital (Guangdong, China). Between
February 2011 and May 2015, a total of 1539 sputum-
smear-negative pulmonary TB suspects who underwent
bronchoscopy for medical diagnosis purpose were in-
cluded in the study. The selection of TB suspects for
bronchoscopy was made at the discretion of the clinic
physicians responsible for their care with no influence
from the investigators implementing this study. Medical
data were collected on age, gender, symptoms, previous
TB history, laboratory test and imaging detection. La-
boratory tests included sputum smear (three times) and
culture, interferon-gamma release assay (IGRA), CD4
and CD8 cell counts. Patients with a follow-up less than
6 months were excluded.
Cases definition
The diagnosis of active TB were following Chinese diag-
nostic criteria for tuberculosis (WS288–2008), WHO
guidelines for treatment of tuberculosis (fourth edition),
and other references [10–12]. Active TB cases were clas-
sified as definite TB and probable TB, the definition and
category of study population were listed below:
Tuberculosis suspect referred to any person who pre-
sented with typical chest imaging suggestive of TB
(WS288–2008).
Definite TB was defined as sputum or BALF culture
positive for Mtb, or NAAT positive for Mtb, plus clinical
symptom and CT sign suggestive of pulmonary TB and
response to anti-tuberculosis treatment.
Probable TB was defined as sputum or BALF culture
and NAAT negative for Mtb, sputum/BALF negative or
positive for AFB, plus clinical symptom and CT sign
suggestive of pulmonary TB and response to anti-
tuberculosis treatment.
Cured TB (RxTB) was defined as the pulmonary TB
patients who had completed standard anti-TB treatment
regimen for at least 6 months with no subsequent evi-
dence of active TB.
Non-TB lung disease (non-TB) was defined as negative
cultures and smears for Mtb detection in sputum and
BALF, CT suggestive of non-TB, and anti-TB treatment
was never initiated by healthcare providers. Non-TB
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lung diseases included bacterial pneumonia, lung cancer,
sarcoidosis, asthma, bronchiectasis, bronchitis, etc.
Non-tuberculous mycobacteria (NTM) infection was
confirmed by identification of the same species of NTM
in sputum and/or BALF.
Bronchoscopy technique, specimen processing and IGRA
All patients underwent bronchoscopy with BALF collec-
tion. Patients were pre-medicated with 0.5 mg atropine
and then sedated with midazolam. Bronchial washing of
the involved sub-segment was performed with 20 to
50 ml of isotonic saline. Sputum samples, if available,
were collected on three consecutive days and examined
for the presence of acid-fast bacilli by microscopy. All
sputum and BALF samples were subjected to NAAT for
detection of Mtb DNA using a commercial quantitative
real-time polymerase chain reaction kit (qPCR) (Qiagen,
China), and mycobacterium culture for up to 6 weeks in
fluid media (MGIT, BD, Heidelberg), or 8 weeks in solid
media (Loewenstein-Jensen), before the results were
concluded negative.
The Mtb-specific IGRA was performed as an in-
house IFN-γ enzyme-linked immunospot assay which
was reported previously [13]. The overall sensitivities
and specificities of our in-house IGRA were similar
to commercial IGRA kits [13].
Statistical analysis
The positive rate, sensitivity, specificity and accuracy of
Mtb tests in sputum and BALF for the diagnosis of pul-
monary TB were calculated.
For categorical variables, the percentage of patients in
each category was calculated. To identify potential vari-
ables related to positivity of BALF (positivity in Mtb de-
tection of BALF through smear microscopy, culture and/
or NAAT), univariate analysis with Pearson’s χ2 test was
performed. All variables with P values less than 0.05 in
univariate analysis were entered into the unconditional
multiple logistic regression analyses and the associations
assessed with Odds ratios (OR) and 95% confidence
intervals (CIs). To identify the overlapping effects on
positivity of BALF, variables with P values less than
0.05 in unconditional multiple logistic regression
analyses were entered into stratified analysis. All analyses
were performed using SPSS software (release 20.0,
IBM,USA).
Fig. 1 Diagnostic flow chart. Abbreviations: NTM, nontuberculosis mycobateria; NAAT, nucleic acid amplification technique; BALF, bronchoalveolar
lavage fluid
Table 1 Clinical characters of pulmonary TB suspects who
underwent bronchoscopy
Final diagnosis Number Age (mean ± SD) Male (%)
Active pulmonary TB 1146 35.0 ± 13.5 636 (55.5%)
Cured tuberculosis 78 42.9 ± 13.3 51 (65.4%)
NTM 25 45.5 ± 15.9 8 (32.0%)
Other lung disease 290 41.4 ± 15.1 170 (58.6%)
Pneumonia 193 40.9 ± 15.9 111 (57.5%)
Lung cancer 34 49.8 ± 13.9 21 (61.8%)
Othersa 62 38.4 ± 11.5 38 (61.3%)
Total 1539 36.8 ± 13.9 865 (56.2%)
TB tuberculosis, NTM nontuberculosis mycobateria
aOthers included sarcoidosis, asthma, bronchiectasis, bronchitis, etc
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Results
Clinical characteristics and final diagnosis of sputum-
smear-negative pulmonary TB suspects
A total of 1539 subjects who underwent bronchoscopy
were enrolled in the study (see Fig. 1). The median age
was 36.8 ± 13.9 (interquartile range, 11 to 81 years old)
and 56.2% were males. There were no complications
from the procedure and BALF samples were obtained
from all patients. Among them, 1146 patients had a final
diagnosis of pulmonary TB, 78 patients were cured TB
but not TB relapse, 25 patients were diagnosed with
NTM infection, and 290 patients had a final diagnosis of
non-TB lung diseases (see Table 1).
Among 1539 suspect TB patients, 620 (40.3%) patients
were negative for sputum Mtb culture or NAAT test, 408
(26.5%) patients had no sputum. Of 1146 suspects with
final diagnosis of pulmonary TB, 304 (26.5%) had no spu-
tum production, 343 (29.9%) were negative for sputum
Mtb detection by smear, culture or NAAT, while 499
(43.5%) were bacteriologically confirmed based on one or
more of these sputum tests. In comparison, 727 of 1146
(63.4%) pulmonary TB patients were bacteriologically con-
firmed by smear, culture or NAAT in BALF. A total of
362 (31.6%) patients had a final clinical diagnosis of pul-
monary TB based on chest imaging and anti-TB treatment
response.
Among 25 NTM lung disease cases who were diagnosed
by conventional mycobacterial culture and 16 s RNA gene
based molecular species identification using BALF sam-
ples, only 48.0% (12/25) cases were identified by sputum
culture. Bronchoscopy made more species identification
possible, from which a correct treatment could be applied.
BALF improved the diagnostic accuracy of sputum-
negative and non-sputum-producing TB suspects
Positive detectable rate, sensitivity, specificity and accur-
acy of different methods for the diagnosis of all sputum-
smear-negative pulmonary TB suspects, sputum negative
and no sputum patients were listed in Tables 2 and 3.
Among the 1539 suspects, the overall positive detection
rate of BALF for diagnosis of pulmonary TB was signifi-
cantly higher than that of sputum, with overall positivity
Table 2 Comparison of sensitivity, specificity, etc. between sputum and BALF for the diagnosis of pulmonary TB in sputum-smear-
negative suspects
Positive detectable rate (%) Sensitivity (%) Specificity (%) Accuracy (%)
Sputum-culture/NAAT 32.4 43.5 100.0 58.0
sputum-culture 26.1 35.1 100.0 51.7
sputum-NAAT 20.7 27.7 100.0 46.2
BALF-smear/culture/NAAT 47.2 63.4 100.0 72.8
BALF-smear 9.2 12.0 99.2 34.3
BALF-culture 42.5 57.1 100.0 68.0
BALF-NAAT 33.2 44.5 99.7 58.6
Sputum+BALF 50.9 68.4 100.0 72.8
TB tuberculosis, BALF bronchoalveolar lavage fluid, NAAT nucleic acid amplification test
Table 3 The performance of BALF based detection for the diagnosis of pulmonary TB in sputum-negative suspects and those
without sputum
Positive detectable rate % Sensitivity % Specificity % Accuracy %
Sputum-negative
BALF-smear/culture/NAAT 19.7 35.6 100.0 64.4
BALF-culture 16.5 29.7 100.0 61.1
BALF-NAAT 11.1 20.1 100.0 55.8
No sputum
BALF-smear/culture/NAAT 40.0 53.6 100.0 65.4
BALF-culture 38.2 51.3 100.0 63.7
BALF-NAAT 24.5 32.9 100.0 50.0
sputum negative and no sputum
BALF-smear/culture/NAAT 27.8 44.1 100.0 64.9
BALF-culture 26.3 41.6 100.0 63.3
BALF-NAAT 16.5 26.3 100.0 53.7
TB tuberculosis, BALF bronchoalveolar lavage fluid, NAAT nucleic acid amplification test
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Table 4 Comparison of clinical characteristics between BALF bacteriologically negative and positive patients within sputum negative
pulmonary TB patients and those without sputum
Total BALF (+) BALF (−) P-value OR (95% CI)
N = 1028 n = 285 n = 743
Age 37.4 ± 14.2 32.7 ± 12.8 39.3 ± 14.2 < 0.001
Male 589 154 (26.1%) 435 (73.9%) 0.191 0.832 (0.632~ 1.096)
TB history 126 40 (31.7%) 86 (68.3%) 0.282 1.247 (0.834–1.866)
Fever 363 94 (25.9%) 269(74.1%) 0.333 0.867 (0.650–1.157)
Night sweat 97 28 (28.9%) 69 (71.1%) 0.792 1.064 (0.670–1.689)
Cough 751 213 (28.4%) 538 (71.6%) 0.451 1.127 (0.825–1.540)
Hemoptysis 158 60 (38.0%) 98 (62.0%) 0.002 1.755 (1.230–2.504)
Lose weight 222 72 (32.4%) 150 (67.6%) 0.077 1.336 (0.969–1.843)
Bilateral lung 268 92 (34.3%) 176 (65.7%) 0.005 1.536 (1.137–2.074)
Cavity 104 57 (54.8%) 47 (45.2%) < 0.001 4.108 (2.376–7.102)
aCD4 595.8 ± 274.4 547.77 ± 246.14 615.8 ± 283.2 0.004
aCD4≤500 264 92 (34.8%) 172 (65.2%) 0.011 1.540 (1.101–2.153)
aCD8 420.0 ± 205.4 380.30 ± 181.83 436.7 ± 212.6 0.001
aCD8≤500 468 153 (32.7%) 315 (67.3%) 0.002 1.992 (1.289–3.076)
ESR 40.9 ± 31.3 46.08 ± 29.97 39.0 ± 31.6 0.001
IGRA (+)b 507 201 (39.6%) 306 (60.4%) < 0.001 3.743 (2.478–5.655)
BALF bronchoalveolar lavage fluid, IGRA interferon-γ release assays, ESR erythrocyte sedimentation rate
aTotal N = 679, BALF (+) n = 199, BALF (−) n = 480
bTotal N = 938, BALF (+) n = 270, BALF (−) n = 692
Table 5 Univariate and multivariate analysis of factors associated with BALF positivity in pulmonary TB sputum-negative suspects
and those without sputum
Total BALF (+) BALF (−) P-value OR (95% CI)a
n = 285 (%) n = 743 (%)
Age (year) < 0.001
≤ 25 244 105 (43.0) 139 (57.0) Reference
25–35 288 88 (30.6) 200 (69.4) 0.582 (0.408–0.832)
35–45 215 44 (20.5) 171 (79.5) 0.341 (0.224–0.517)
45–55 128 22 (17.2) 116 (82.8) 0.251 (0.149–0.423)
55–65 106 23 (21.7) 83 (78.3) 0.367 (0.217–0.621)
> 65 37 3 (8.1) 34 (91.9) 0.117 (0.035–0.391)
Cavity < 0.001
No 924 228 (24.7) 696 (75.3) Reference
Yes 104 57 (54.8) 47 (45.2) 4.108 (2.376–7.102)
IGRA < 0.001
Negative 431 64 (14.8) 367 (85.2) Reference
Positive 507 201 (39.6) 306 (60.4) 3.743 (2.478–5.655)
CD8+ 0.002
> 500 205 46 (22.5) 159 (77.5) Reference
≤ 500 468 153 (32.7) 315 (67.3) 1.992 (1.289–3.076)
TB tuberculosis, BALF bronchoalveolar lavage fluid, NAAT nucleic acid amplification test, IGRA interferon-γ release assays
aControlling for variables with P < 0.05 in univariate analysis
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of 47.2% and 32.4%, respectively. The overall sensitivity of
BALF (63.4%) was significantly higher than that of sputum
(43.5%) (see Table 2). Compared to sputum, an increased
sensitivity of BALF was observed in all three Mtb tests in-
cluding AFB staining, Mtb culture and NAAT, indicating
that BALF samples were enriched for Mtb. Specifically,
122 (19.7%) out of 620 pulmonary TB patients who were
negative for all three Mtb tests in sputum were eventually
confirmed by positive results for one or more of these
tests in BALF. Notably, the benefit of BALF was mostly
evident in those pulmonary TB suspects without sputum
production. As shown in Table 3, 163 (40.0%) out of 408
pulmonary TB patients without sputum production were
bacteriologically confirmed by BALF Mtb tests.
Factors associated with positive BALF Mtb detection in
sputum-negative and non-sputum-producing pulmonary
TB patients
In line with previous literature [14], our data demon-
strated that BALF significantly improved Mtb detection
in pulmonary TB patients. More importantly, BALF
significantly improved the diagnosis and treatment of
those pulmonary TB patients who were unable to pro-
duce sputum. Isolating Mtb in those cases was not only
critical for TB diagnosis, but also permitted drug suscep-
tibility testing. Despite the clear benefit of bronchoscopy
in the management of individual cases, only 285 (27.7%)
subjects were positive for Mtb detection in BALF among
1028 subjects with sputum negative or without sputum.
To identify those patients most likely to benefit from
bronchoscopy, we analyzed the clinical parameters asso-
ciated with Mtb detection in BALF among sputum-
negative pulmonary TB suspects and TB suspects who
were unable to produce sputum. Univariate analysis
showed that age (P < 0.001), hemoptysis (P = 0.002),
bilateral lung infection (P = 0.005), cavity on chest ra-
diographs (P < 0.001), CD4 cell count (P = 0.004), CD8
cell count (P = 0.001), erythrocyte sedimentation rate (P =
0.001), and IGRA results (P < 0.001) were all significantly
associated with Mtb detection in BALF (see Table 4).
Multivariate logistic regression analysis revealed that age,
cavity on chest radiographs (OR: 4.108, 95% CI: 2.376–
Table 6 Stratified analysis of factors associated with BALF positivity in pulmonary TB sputum-negative suspects and those without
sputum
BALF (+) n/N (%) BALF (−) n/N (%) P-value OR (95% CI)
IGRA/Age <0.001
IGRA (−)/> 35 year 30/239 (12.6) 209/239 (87.4) Reference
IGRA (−)/≤ 35 year 34/192 (17.7) 158/192 (82.3) 1.499 (0.880–2.554)
IGRA (+)/> 35 year 55/212 (25.9) 157/212 (74.1) 2.441 (1.494–3.986)
IGRA(+)/≤ 35 year 146/295 (49.5) 149/295 (50.5) 6.826 (4.372–10.658)
Cavity/Age <0.001
Cavity (−)/> 35 year 76/453 (17.0) 371/477 (83.0) Reference
Cavity (−)/≤ 35 year 152/477 (31.9) 325/477 (68.1) 2.283 (1.669–3.122)
Cavity (+)/> 35 year 16/49 (32.7) 33/49 (67.3) 2.367 (1.240–4.516)
Cavity (+)/≤ 35 year 41/55 (74.5) 14/55 (25.5) 14.296 (7.426–27.521)
CD8/Age <0.001
CD8> 500/> 35 year 16/82 (19.5) 66/82 (80.5) Reference
CD8> 500/≤ 35 year 30/117 (25.6) 87/117 (74.4) 1.422 (0.716–2.824)
CD8≤ 500/> 35 year 49/222 (22.1) 173/222 (77.9) 1.168 (0.621–2.197)
CD8≤ 500/ ≤ 35 year 104/246 (42.3) 142/246 (57.7) 3.021 (1.655–5.515)
IGRA/Cavity/Age <0.001
IGRA (−)/Cavity (−)/> 35 year 24/219 (11.0) 195/219 (89.0) Reference
IGRA (−)/Cavity (−)/≤ 35 year 23/174 (13.2) 151/174 (86.8) 1.238 (0.672–2.278)
IGRA (−)/Cavity (+)/> 35 year 6/20 (30.0) 14/20 (70.0) 3.482 (1.223–9.912)
IGRA (−)/Cavity (+)/≤ 35 year 11/18 (61.1) 7/18 (38.9) 12.768 (4.521–36.056)
IGRA (+)/Cavity (−)/> 35 year 45/184 (24.5) 139/184 (75.5) 2.630 (1.531–4.519)
IGRA (+)/Cavity (−)/≤ 35 year 118/262 (45.0) 144/262 (55.0) 6.658 (4.083–10.856)
IGRA (+)/Cavity (+)/> 35 year 10/28 (35.7) 18/28 (64.3) 4.514 (1.869–10.901)
IGRA (+)/Cavity (+)/≤ 35 year 28/33 (84.8) 5/33 (15.2) 45.500 (16.054–128.955)
TB tuberculosis, BALF bronchoalveolar lavage fluid, IGRA interferon-γ release assays
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7.102), IGRA result (OR: 3.743, 95% CI: 2.478–5.655), and
CD8 counts (OR: 1.992, 95% CI: 1.289–3.076) were inde-
pendent risk factors associated with the positivity of Mtb
detection in BALF (see Table 5). Further analysis indicated
that combination of age, cavity on chest radiographs, and
IGRA yielded the highest positivity of Mtb detection in
BALF. Specifically, younger pulmonary TB suspects (≤
35 years old) with cavity on chest radiographs and positive
IGRA had 84.8% (28/33) positivity of Mtb detection in
BALF (see Table 6).
Discussion
Negative diagnostic tests on sputum samples and lack of
sputum production in patients with pulmonary TB have
been reported to be the major causes of treatment delay
[15]. In our study, the sensitivity of sputum Mtb tests in-
cluding sputum Mtb culture and NAAT was 43.5% (499/
1146) in pulmonary TB patients. In paired comparison,
63.4% of (727/1146) pulmonary TB patients were bac-
teriologically confirmed by BALF Mtb tests. In addition,
13 out of 25 patients with NTM infection were diag-
nosed by BALF-based tests. Thus, about 30% patients
benefited from BALF Mtb tests. It is worthy to note that
BALF Mtb tests increased 35.6% and 53.6% positivity in
sputum-negative and non-sputum-producing pulmonary
TB patients, respectively. BALF not only increased the
positive rate of bacteriological detection for diagnosis,
but also made a significant improvement for effective
precision treatment through enabling species identifica-
tion and drug susceptibility testing.
While bronchoscopy is clearly a useful diagnostic tool
for pulmonary TB, it has risks of hemorrhage, pneumo-
thorax, laryngospasm as well as other minor and major
potentially adverse effects [16, 17]. Nosocomial trans-
mission of TB and other pathogens might also occur in
some patients exposed to inadequately sterilized bron-
choscopy equipment. Furthermore, bronchoscopy is an
expensive procedure requiring expert personnel and fa-
cilities. Therefore, we identified clinical parameters asso-
ciated with positivity of Mtb detection in BALF in an
attempt to maximize the benefit of BALF collection for
pulmonary TB suspects who undergo bronchoscopy. We
found that age, cavity on chest radiographs, IGRAs re-
sults, and CD8+ T cell count are risk factors associated
with positivity of BALF Mtb tests. By the stratified ana-
lysis, we determined that age, cavity on chest radio-
graphs, IGRAs results, but not CD8+ T cell count, have
an overlay effect in predicting positivity of Mtb tests in
BALF. Specifically, a combination of age (≤ 35 years),
IGRAs (+), cavity on chest radiographs had yielded a sig-
nificantly high positivity (84.8%) of Mtb detection in
BALF.
Among these factors, cavity on radiograph has the
highest predictive value, which might be expected, as
the cavities developed by erosion of caseation granu-
lomas into bronchi, through which Mtb can be ex-
pelled [18]. In support of this, a previous report
indicated numerous AFB are detected at the surface
of cavities [19]. In the present study, age ≤ 35 years
and positive IGRAs results were predictive factors for
positive BALF results. Although IGRAs cannot reli-
ably distinguish active TB from latent TB infection,
we and other researchers have shown that the levels
of IFN-γ determined by IGRAs are associated with
sputum Mtb positivity in immune competent pulmon-
ary TB patients [20], and the sensitivity of IGRAs is
correlated with paucibacillary nature of the samples
[21]. In line with these findings, here we found
IGRAs alone has a predictive odds ratio of 3.743
(95% CI: 2.478–5.655) for Mtb positivity in BALF, due
to the existence Non-TB patients in the BALF-
negative TB suspects. We speculate that younger pa-
tients capable of mounting a robust cell-mediated im-
mune response to pulmonary TB are more likely to
develop cavitary lesions with positive sputum and
BALF tests for Mtb.
Conclusions
We found that age (≤ 35 years), positive IGRA test and
cavity on chest radiographs as risk factors associated
with positivity of Mtb detection in BALF. Sputum nega-
tive pulmonary TB suspects who are under 35 years old,
positive for the presence of pulmonary cavity and IGRA,
should undergo bronchoscopy to collect BAFL for Mtb
tests, as they have the highest possibility to get bacterio-
logically confirmation of TB.
Additional file
Additional file 1: Multilingual abstracts in the six official working
languages of the United Nations. (PDF 714 kb)
Abbreviations
AFB: Acid fast bacilli; BALF: Bronchoalveolar lavage fluid; CDC: Center for
Disease Control and Prevention; CIs: Confidence intervals; IGRAs: Interferon-
gamma release assays; LPAs: Line probe assays; LTBI: Latent TB infection;
MDR-TB: Multi-drug resistant TB; Mtb: Mycobacterium tuberculosis;
NAAT: Nucleic acid amplification test; NTM: nontuberculous mycobacteria;
ORs: Odds ratios
Acknowledgements
We would like to thank all study participants who were involved and
contributed to the data collection. We thank editors and reviewers for their
warm works and valuable comments.
Funding
This study was supported by National Nature Science Foundation of China
(81525016, 81772145, 81770013), Shenzhen Science & Technology Grant
(JSGG20160427104724699, JCYJ20170412101048337, JCYJ20170412151620658),
and Sanming Project of Medicine in Shenzhen (GCZX2015043015340574).
Liu et al. Infectious Diseases of Poverty  (2018) 7:22 Page 7 of 8
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
XL, X-FH, Q-TY, M-XZ, Z-HW and H-YL performed the study. XL and X-FH
analyzed the data and wrote the manuscript. G-FD, Q-YD, T-SY and provided
clinical data. LG helped the statistical analysis. HK helped edit the paper. B-PZ
and X-CC supervised the study and applied for grants. XL and X-CC were
identified as the guarantor of the paper, taking responsibility for the integrity
of the work as a whole, from incepton to published article. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Shenzhen Third
People’s Hospital, and informed consent was obtained from each participant.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Shenzhen Key Laboratory of Infection & Immunity, Shenzhen Third People’s
Hospital (The Second Affiliated Hospital of Shenzhen University), Shenzhen
University School of Medicine, Shenzhen, China. 2Department of Infectious
Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
3Ministry of Health Key Laboratory of Systems Biology of Pathogens, Institute
of Pathogen Biology, Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing, China. 4Department of Medicine, University
of Massachusetts Medical School, Worcester, MA 01655, USA. 5Yuebei Second
People’s Hospital, Shaoguan, China. 6Department of Pathogen Biology,
Shenzhen University School of Medicine, Shenzhen 518054, China.
Received: 12 July 2017 Accepted: 12 March 2018
References
1. World Health Organization. Global tuberculosis report 2016. http://apps.
who.int/medicinedocs/en/d/Js23098en/. Accessed 17 Dec 2017.
2. Horsburgh CJ, Barry CR, Lange C. Treatment of tuberculosis. N Engl J Med.
2015;373:22.
3. Trebucq A, Devi S. Widespread use of Xpert((R)) MTB/ NAAT will most
probably reduce the total number of TB cases notified. Int J Tuberc Lung Dis.
2015;19:11.
4. Luetkemeyer AF, Kendall MA, Wu X, Lourenco MC, Jentsch U, Swindells S, et
al. Evaluation of two line probe assays for rapid detection of Mycobacterium
tuberculosis, tuberculosis (TB) drug resistance, and non-TB mycobacteria in
HIV-infected individuals with suspected TB. J Clin Microbiol. 2014;52:4.
5. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic
accuracy of commercially based nucleic acid amplification tests for the
diagnosis of pulmonary tuberculosis. Thorax. 2006;61:9.
6. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of
the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis
when testing non-respiratory samples: a systematic review. BMC Infect Dis.
2014;14:709.
7. George PM, Mehta M, Dhariwal J, Singanayagam A, Raphael CE, Salmasi M,
et al. Post-bronchoscopy sputum: improving the diagnostic yield in smear
negative pulmonary TB. Respir Med. 2011;105:11.
8. Tian P, Shen Y, Wang Y, Wan C, Feng M, Zhu J, et al. Diagnostic value of
nucleic acid amplification tests on bronchoalveolar lavage fluid for smear-
negative pulmonary tuberculosis: a meta-analysis. Biosci Rep. 2015;35:4.
9. Soto A, Acurio V, Solari L, Van der Stuyft P. Incremental yield of bronchial
washing for diagnosing smear-negative pulmonary tuberculosis. Rev Saude
Publica. 2013;47:4.
10. World Health Organization. Treatment of tuberculosis-guidelines for national
programmes, fourth edition. 2010. http://www.who.int/tb/publications/
9789241547833/en/. Accessed 17 Dec 2017.
11. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis
prevalence in China, 1990-2010; a longitudinal analysis of national survey
data. Lancet. 2014;383:9934.
12. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A,
et al. Diagnostic performance of a seven-marker serum protein biosignature
for the diagnosis of active TB disease in African primary healthcare clinic
attendees with signs and symptoms suggestive of TB. Thorax. 2016;71:9.
13. Chen X, Yang Q, Zhang M, Graner M, Zhu X, Larmonier N, et al.
Diagnosis of active tuberculosis in China using an in-house gamma
interferon enzyme-linked immunospot assay. Clin Vaccine Immunol.
2009;16:6.
14. Chou PC, Wang CH, Huang CD, Lo YL, Lee KY, Yu CT, et al. Nucleic acid
amplification test and bronchoscopy improve the diagnostic accuracy of
smear-negative tuberculosis. Int J Tuberc Lung Dis. 2012;16:12.
15. Castro ATE, Mendes M, Freitas S, Roxo PC. Diagnostic yield of sputum
microbiological analysis in the diagnosis of pulmonary tuberculosis in a
period of 10 years. Rev Port Pneumol. 2015;21:4.
16. Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-Mendoza J, et al. Diagnostic
yield and complications of bronchoscopy for peripheral lung lesions. Results of
the AQuIRE registry. Am J Respir Crit Care Med. 2016;193:1.
17. Fernandez-Bussy S, Labarca G, Zagolin M, Oyonarte M, Isamit D, Jalilie A, et
al. Immediate complications following flexible bronchoscopy: retrospective
analysis of 1079 procedures. Rev Med Chil. 2014;142:3.
18. Hunter RL. On the pathogenesis of post primary tuberculosis: the role of
bronchial obstruction in the pathogenesis of cavities. Tuberculosis (Edinb).
2011;91(Suppl 1):S6–10.
19. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et
al. Mycobacterium tuberculosis growth at the cavity surface: a
microenvironment with failed immunity. Infect Immun. 2003;71:12.
20. De Keyser E, De Keyser F, De Baets F. Tuberculin skin test versus
interferon-gamma release assays for the diagnosis of tuberculosis
infection. Acta Clin Belg. 2014;69:5.
21. Liu F, Du FJ, Jia HY, Pan LP, Zhang X, Xing AY, et al. Inadequate values from
an interferon-gamma release assay for smear-negative tuberculosis in a
high-burden setting. Int J Tuberc Lung Dis. 2014;18:12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liu et al. Infectious Diseases of Poverty  (2018) 7:22 Page 8 of 8
